Navigation Links
Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
Date:9/25/2007

SAN DIEGO, Sept. 25 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today announced that enrollment is complete in its Chemophase(R) Phase I/IIa clinical trial for the treatment of superficial bladder cancer. The Company began dosing patients in this trial in April of last year, following the successful completion of the initial Phase I trial of a single-administration of Chemophase and mitomycin. Patient enrollment in this Phase I/IIa trial required stepwise enrollment by escalating dose cohort, with a pause for safety evaluation required after the last patient in the previous cohort had completed at least the first four of the six weekly study drug instillations. Chemophase is a novel recombinant investigational therapeutic being developed to enhance the delivery of chemotherapy.

The Chemophase Phase I/IIa clinical trial is a multi-center, open label, nonrandomized study to evaluate multiple intravesical (into the bladder) administrations of Chemophase along with the widely used anticancer drug mitomycin in patients with superficial bladder cancer. This dose-finding Phase I/IIa study enrolled 27 patients with superficial bladder cancer. The objectives of the study included determining the maximum tolerated dose (MTD) and dose-limiting toxicities, if any, of escalating doses of mitomycin and then Chemophase in combination with mitomycin administered as weekly intravesical instillations for six weeks, consistent with the usual standard of care; establishing the optimal dose of Chemophase with mitomycin to be recommended for future studies; and observing patients for any preliminary evidenc
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... CHAPEL HILL, N.C. , June 11 ... groups is a critical part of educating patients and ... consumers as they seek out information on new therapies, ... deep-dive interviews with selected participants, Best Practices, LLC conducted ...
... HILL, N.C. , June 11 The bio-pharma mega-mergers that ... Merck + Schering-Plough - are now in the critical post-integration period and ... their integration plans. , , ... It is too early for final verdicts, but clearly one M&A issue ...
Cached Medicine Technology:Collaborating with Patient Advocacy Groups to Educate Physicians, Patients and Thought Leaders 2Benchmarking Study Reveals What Bio-Pharma Companies Need to Know to Achieve Successful Integration after an Acquisition or Merger 2Benchmarking Study Reveals What Bio-Pharma Companies Need to Know to Achieve Successful Integration after an Acquisition or Merger 3
(Date:7/9/2014)... extinctions around the world have been linked to ... research from the National Institute for Mathematical and ... may also contribute. , In a series ... causes severe hemorrhage of internal organs in frogs, ... frogs if they are exposed to the virus ...
(Date:7/9/2014)... of Allergy and Infectious Diseases (NIAID), part of ... early-stage clinical trial of CRS3123, an investigational oral ... ( C. difficile ) infection. CRS3123 (previously known ... C. difficile growth while sparing normal intestinal bacteria. ... to 30 healthy men and women ages 18 ...
(Date:7/9/2014)... prescription labels handed out by pharmacists may be ... medication, according to new research by the University ... the Blind)., The study, published recently in the ... on prescription medications dispensed by pharmacies do not ... By simply following recommended guidelines for font size, ...
(Date:7/9/2014)... published in the scientific journal Nature Neuroscience ... at Universit Laval, reveals that it is possible to ... rekindling pain so that it can subsequently be erased. ... chronic pain. , The researchers from the Faculty of ... mentale de Qubec (IUSMQ) were inspired by previous work ...
(Date:7/8/2014)... enjoy similar longevity and cardiovascular health as other healthy ... the American Journal of Transplantation . The findings ... and the transplant professionals caring for them. , Over ... aged 55 years and older has become more common. ... heart disease, the removal of a kidney could make ...
Breaking Medicine News(10 mins):Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Discovery of a new means to erase pain 2Health News:Study finds kidney donation safe for healthy older adults 2
... black young adults are hospitalized for stroke at a ... peers, a new study by University of South Florida ... the American Heart Association,s Council on Epidemiology and Prevention ... the international journal Neuroepidemiology . , Disparities ...
... the only Minnesota hospitals to receive designation ROCHESTER, Minn., ... Surgical Quality Improvement Program (ACS NSQIP) has recognized Mayo ... of the 26 ACS NSQIP participating hospitals in the ... patient care. As a participant in ACS NSQIP, Mayo ...
... NEW YORK, March 13 Ruth W. Messinger, ... issued a statement today calling on the international ... international aid organizations into Darfur so workers can ... refugees and internally displaced persons throughout Darfur and ...
... Rice University report released yesterday, exactly six months after ... people did not practice the lessons learned from Hurricane ... Harris County residents say they would evacuate if a ... potential increase over the 24 percent of residents who ...
... print news decline and consumer shift to web news -LITTLE FALLS, ... New York Times reports on the closing ... 24/7 Wall St. issued its list of 10 major daily ... only publish online. While the New York Times ...
... with language disorders may benefit from tonal training , , ... the ability to recognize emotion in speech and other ... benefit people with language problems and impaired emotional perception. ... is a skill that translates across all arenas, whether ...
Cached Medicine News:Health News:Black young adults hospitalized for stroke at much higher rate than whites, Hispanics 2Health News:Black young adults hospitalized for stroke at much higher rate than whites, Hispanics 3Health News:American College of Surgeons Recognizes Mayo Hospitals for Exemplary Outcomes 2Health News:American College of Surgeons Recognizes Mayo Hospitals for Exemplary Outcomes 3Health News:Rice report shows lessons from Hurricane Rita not practiced during Ike 2Health News:Print Media Under Siege - Are Readers Disappearing? 2Health News:Musicians' Brains Tuned to Emotions in Sound 2
... of healthcare associated infections can be prevented with ... action a healthcare worker can do to reduce ... Alcohol gel hand sanitization is fast, easy to ... with soap and water. , Aplicare's 62% Ethyl ...
This is long known for its purity and mildness, Castile Soap is also an effective cleaning agent that is used in a variety of applications. It rinses clean while leaving the skin soft and healthy....
... not leave your hands dry, cracked or ... Antimicrobial action, CHG Skin Cleanser attacks a ... gram-positive bacteria, fungi, and yeasts. It is ... wash. The solution does not contain red ...
BD Persist Plus protective barrier skin preps with chlorhexidine in alcohol...
Medicine Products: